Microbiology (original) (raw)
Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.
Sign up for access to the world's latest research.
checkGet notified about relevant papers
checkSave papers to use in your research
checkJoin the discussion with peers
checkTrack your impact
Related papers
Pretest Microbiology 10th (2002)
Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.
2015
PURPOSE: To provide a forum for discussion of microbiology issues in the pharmaceutical and related industry. The information contained in this newsletter includes the professional opinions of individuals and does not represent the policies or operations of any corporation or government agency to which they may be associated. PMF Newsletter is intended to serve as an open forum. The information in PMF Newsletter is solely for informational purposes and is developed from sources believed to be reliable. Statements expressed constitute current opinions derived through analysis of available information and professional networking. Articles or opinions are for infor-mation only to stimulate discussion and are not necessarily the views of the PMF board or regulatory agencies. The PMF Newsletter cannot make any representations as to the accuracy or completeness of the information presented and the publisher cannot be held liable for errors.
A Publication of the Pharmaceutical Microbiology Forum DISTRIBUTED INTERNATIONALLY
2015
PURPOSE: To provide a forum for discussion of microbiology issues in the pharmaceutical and related industry. The information contained in this newsletter is the professional opinions of individuals and does not represent the policies or operations of any corporation or government agency to they may be associated. PMF Newsletter is intended to serve as an open forum. The information in PMF Newsletter is solely for information purposes and is developed from sources believed to be reliable. State-ments expressed constitute current opinions derived through analysis of available information and professional networking. Articles or opinions are for information only to stimulate discussion and are not necessarily the views of the PMF board or regulatory agencies. The PMF Newsletter cannot make any representations as to the accuracy or completeness of the information presented and the publisher cannot be held liable for errors.
IMMUNOLOGY AND MEDICAL MICROBIOLOGY Antimicrobial Chemotherapy
2000
CONTENTS Introduction Antibiotics Effects of combining antimicrobial agents Inhibition of bacterial cell wall synthesis Antibacterial agents affecting bacterial cell membrane function Antibacterial agents that inhibit nucleic acid metabolism Antibacterial agents that inhibit RNA metabolism Antibacterial agents that inhibit protein synthesis Anti-mycobacterial drugs Antifungal agents Antiviral agents Antibiotic resistance in bacteria
This study is a follow up of the study with urine samples in which the value of the PREVI Isola (bioMérieux) system in the routine diagnostic laboratory was analyzed (ECCMID 2009 − Ab.Nr. 1459. PREVI Isola is a system for automated inoculation and streaking and is able to process any material from patients (liquid format). For urine samples we observed less sub culturing and earlier identification resulting in saving labor time and costs. The aim of this study was to explore the usefulness of the PREVI Isola for more difficult samples as feces and genital swabs. Methods: Feces or genital swabs from 100 different patients were processed manual and by the PREVI Isola. Fecal samples were cultured for Campylobacter (Campylobacter agar), Salmonella and Shigella (XLD-agar) and Yersinia (Yersinia agar). Genital swabs were cultured for aerobic bacteria (blood agar), anaerobic bacteria (anaerobic blood agar), Neisseria gonorrhoeae (GO agar), Gardnerella vaginalis (Gardnerella agar) and for yeasts (Sabouraud agar). For the PREVI Isola both feces (20 ml) and the genital swabs were suspended in 2.5 ml NaCl. Results for fecal samples: All samples could be evaluated. No Salmonella or Shigella was found. In 5 samples a Campylobacter was found but with the PREVI Isola individual, suspected colonies were better distinguished and were seen earlier (after 1 day). High counts of Yersinia were found in 1 sample but only with the PREVI Isola method. Results for genital swabs: In general counts of the different bacteria were somewhat higher (+) with the PREVI Isola method than after manual inoculation. With PREVI Isola individual colonies of the different bacteria were much better distinguished No difference in the isolation of gonococci (3 samples) was seen with both methods. Gardnerella was 1 day earlier seen and much easier distinguished from other bacteria with the PREVI Isola method. Conclusions: As with urine samples PREVI Isola leads to better readable results for the more difficult cultures of feces and genital swabs: individual suspected colonies were better distinguished and counts were higher. Cultures were also often 1 day earlier positive for suspected colonies. Therefore PREVI Isola is very useful in the time consuming culture of especially genital swabs but also for fecal cultures in which identification can be done earlier.
Loading Preview
Sorry, preview is currently unavailable. You can download the paper by clicking the button above.